EPSTEIN-BARR VIRUS LMP1 ENHANCES LEVELS OF MICROVESICLE-ASSOCIATED PD-L1

Monica Abou Harb¹, Li Sun¹, David G. Meckes Jr.^{1*}

¹ Department of Biomedical Sciences, Florida State University College of Medicine, Tallahassee, FL, 32306

* Corresponding author

David G. Meckes Jr.

1115 West Call Street

Tallahassee, FL 32306-4300

Phone: (850) 645-2330

Fax: (850) 644-5781

david.meckes@med.fsu.edu

Abstract:

Extracellular vesicles (EVs) circulate throughout the body and carry cargo that can be conferred to proximal or distant cells, making them major delivery vehicles for cellular communication. Epstein-Barr virus (EBV) infected cells release EVs that contain viral proteins such as the major viral oncogene, latent membrane protein 1 (LMP1). LMP1 has been shown to regulate the cellular gene expression of programmed cell death protein 1 ligand (PD-L1). PD-L1, a protein that suppresses the immune system by binding to PD-1, (a receptor found on cytotoxic T cells). PD-L1 has been recently found to be packaged into small EVs contributing to immune evasion of lung cancer cells. Recent studies establish that MVs are shed in very large amounts by tumor cells, and that elevated levels of MVs correlate to disease metastasis and cancers being more aggressive. Here, we demonstrate PD-L1 enrichment in MVs released from nasopharyngeal carcinoma cells and an important function of EBV LMP1 in regulating PD-L1 levels in MVs. These PD-L1+ MVs containing LMP1 likely contribute to the immunosuppressive microenvironment found in EBV-associated cancers.

Importance:

Accumulating evidence over the past decade supports that viruses utilize EVs and associated pathways to incorporate viral products to evade eliciting an immune response, while concurrently enabling viral spread or persistence within the host. Considering that viral proteins confer very strong antigenic peptides that will be recognized by T cells, the regulation of the PD-1 pathway by the overexpression of MV-associated PD-L1 may be a strong immune evasion tactic utilized by viruses. The discovery that EBV LMP1 increases PD-L1 microvesicle secretion, identifies a new therapeutic target in immune blockade therapy. We expect that our

findings will begin to clarify the mechanism of LMP1-mediated enhanced packaging of PD-L1 into MVs and may produce more specific targets to treat EBV-associated cancers. Consequently, identifying whether a disease is of viral origin through predictive MV biomarkers could further allow for more targeted therapies.

KEYWORDS: Epstein-Barr virus, microvesicles, extracellular vesicles, human herpesviruses, PD-L1, LMP1, oncosome, exosomes

Introduction

Epstein-Barr virus (EBV) is a human herpesvirus that persistently infects over 90% of the world's population (1). Most individuals are asymptomatic; however, in immunocompromised or genetically susceptible individuals, EBV infection can cause various lymphomas and carcinomas (1). PD-L1 normally functions by suppressing an individual's immune system from attacking their own cells within the body. Any pathogenic, viral, or foreign substance trying to invade the body is combated by the immune system; however, certain cancer cells take advantage of the functions of PD-L1 and overexpress this gene in order to escape immune detection and maintain proliferation and survival. PD-L1 exists in the blood in two different forms: extracellular vesicle-associated or a soluble protein. One of the first observations of PD-L1 being expressed on small extracellular vesicles (EVs) was in 2011 where investigators detected exosomal PD-L1 extracted from human samples of plasma and urine (2). Additionally, PD-L1 has been found on the surface of antigen presenting cells such as B cells, mast cells, and certain epithelial and endothelial cells (3, 4). It is highly expressed on the

surface of tumor cells, T lymphocytes and tumor associated macrophages (5). Additionally, it can be found in many tissues such as muscles and nerves (6). PD-L1 suppresses the immune system by binding to PD-1, a receptor found on cytotoxic T cells. The PD-1 pathway involves several interactions leading to the inhibition of T-regulatory functions and the production of interleukins which results in a reduced immune response, T cell apoptosis and exhaustion, and the suppression of dendritic cells (7). These cumulative immunosuppressive effects create a very strong protective barrier for cancerous cells to grow uncontrollably and eventually metastasize throughout the body. PD-L1 may also play an important role in immune evasion strategies adopted by viruses and other human pathogens.

Some of the more recent data has suggested an important role for the PD-L1 ligand as a mechanism of achieving an immune resistant tumor microenvironment and establishing latency within the host in EBV infection. Expression of PD-L1 is significantly higher in EBV positive cells compared to EBV negative cells (8). It has been shown that high EBV copy number per infected cell is correlated with PD-L1 expression such as in EBV associated gastric carcinoma (9). The presence of high levels of PD-1 and PD-L1 in EBV+ patients is directly linked to the development of high-risk Hodgkin lymphoma (10). Considering that LMP1, (major viral oncogene expressed in EBV associated cancers), has been established in regulating PD-L1 levels within the cell and manipulates EV cargo and functions, we hypothesized that LMP1 may influence PD-L1 EV levels as an immune evasion mechanism. Ultimately, this would result in an immunosuppressive tumor microenvironment favoring viral sustainability and propagating infection, not only to neighboring cells, but cells throughout the body as well.

Viruses share many similarities with EVs, such as the transfer of functional cellular proteins, RNAs, and miRNAs into neighboring cells (11). The formation of large EVs or microvesicles (MVs) involves transport of cargo to the plasma membrane, lipid membrane redistribution, budding, and finally a form of vesicle pinching upon reaching the membrane which leads to the release of the vesicle (12). Shed MVs are distinct in size, cargo, and mechanism of formation from the other subpopulation of EVs known as small EVs. Both small EVs and MVs encapsulate and transfer cargo including proteins, miRNAs, and RNA transcripts to other cells. Caveolin-1 is essential for sorting of selected miRNAs into MVs (13). Both viruses and MVs emerge from the plasma membrane at lipid raft organizing centers indicating a similar form of biogenesis (14). Elevated levels of EVs in tumor microenvironments and within the circulation correlate to a more advanced disease stage in cancers. MVs play a role in acting as a bridge of cellular communication between cancer and the surrounding stroma to alter the surrounding tumor environment in a way that enhances their growth and survival. MVs shed from a highly metastatic melanoma cell line, were able to confer metastatic characteristics to poorly metastatic cells (15). Recent data has indicated a role for PD-L1 expression in small EVs; however, little is known about PD-L1 expression in MVs, the mechanism that leads to its upregulation, and the localization of PD-L1 in these different EV subpopulations.

Previous studies have already implicated a role for MVs in immune suppression. For example, MVs derived from colorectal carcinoma or human melanoma, suppressed monocyte differentiation into antigen presenting cells and suppressed T lymphocytes through TGF- β , both *in vivo* and *in vitro* (16). LMP1, (a major viral oncoprotein present in EVs), has been shown to be involved in indirectly inhibiting humoral immune response(17, 18). LMP1 has a major role in the lifecycle of EBV, is an important contributor to many EBV-associated cancers,

and is packaged and released from infected cells into small EVs (19). LMP1 activates several signaling pathways such as the JAK/STAT, MAPK, and NF-KB pathways which have been shown to upregulate PD-L1 expression as well and are known to be commonly constitutively activated in a multitude of cancers (19). Here we demonstrate the enrichment of PD-L1 in MVs in response to levels of LMP1 and clarify localization, co-immunoprecipitation, and the regulation of these MVs in response to LMP1 levels.

Results:

PD-L1 levels are elevated in MVs from NPC cells with LMP1 expression.

EBV infected cells have different expression of viral transcriptional programs referred to as latency I, II, and III. EBV Latency II, was originally identified in biopsies of NPC, which was characterized by the co-expression of LMP1, LMP2, and EBNA1 transcripts (20). NPC tissues expressing LMP1 are significantly associated with poor overall survival in NPC patients and lymph node metastasis (21, 22). We decided to investigate two different NPC cell lines with varying levels of LMP1. In the first model, an EBV-negative nasopharyngeal carcinoma cell line (HK1) was compared to HK1 containing a GFP-tagged LMP1 tetracycline-inducible system (HK1 LMP1). The HK1 LMP1 cells were treated with doxycycline to activate LMP1 expression (Fig. 1 A). Additionally, to investigate PD-L1 expression in the context of lower stable expression of LMP1, EBV-negative nasopharyngeal carcinoma (HNE-1) cells were used. HNE-1 cells were transduced with a vector control (pBabe) or hemagglutinin (HA)-tagged LMP1 retroviral vector (HNE-1 pBabe LMP1) that constitutively expresses low levels of LMP1 (Fig. 1 B). LMP1 expression was detectable in the HNE-1 pBabe LMP1 but notably lower than the HK1 LMP1 inducible model. The lower levels of LMP1 have been previously reported to

closely exhibit expression patterns found in EBV-infected cell lines (23). We harvested the cell lysates, apoptotic bodies (2K), microvesicles (10K), and small EVs (100K), and analyzed them by immunoblot (24). The results showed an increase in PD-L1 levels with elevated levels of LMP1, with PD-L1 noticeably enriched within the MV subpopulation of EVs compared to small EVs and apoptotic bodies (Fig 1.A and B). Quantification of the levels of LMP1 and PD-L1 specifically in the MV subpopulation normalized to levels of (HK1 and HNE-1) showed a significant increase in PD-L1 and LMP1 in the MVs of the NPC cell lines expressing LMP1 compared to the wild type cell lines with no LMP1 (Fig. 1C and D). Quantification also demonstrated higher PD-L1 expression in the MVs compared to the other two subpopulations of EVs as seen in (Fig. 1 E and F). In conclusion, these results further support the correlation between LMP1 expression and increased PD-L1 being released from the cell in association with MVs.

PD-L1 is upregulated at the transcriptional level in LMP1 expressing cells and detected in MVs.

To further understand whether PD-L1 is also being impacted at an mRNA level due to LMP1 expression, RT-qPCR was performed on cells and MVs from both HK1 wild type cells and HK1 LMP1 induced cells. HK1 LMP1 containing cells significantly increased the expression of PD-L1 and EV biogenesis related genes (CD9, CD63, CD81, Sytenein-1, and HRS) compared to HK1 cells (Fig. 2A). Interestingly, LMP1 expression did not influence the mRNA levels of PD-L1 in MVs but did have significantly higher levels of CD9, CD63, CD81, Syntenin-1, and HRS mRNA when compared to HK1 (Fig. 2B). CD9, CD63 and CD81 are endosome-specific tetraspanins that are enriched in exosome (samall EV) membranes. CD63 has been found to regulate EBV LMP1 exosomal packaging (18) and HRS and Syntenin-1 have previously been

shown to induce EV formation through EBV LMP1 (25). Altogether, this data suggests that PD-L1 is upregulated at the transcriptional level in LMP1 expressing cells but the level of mRNA transcripts in the MVs remain unchanged.

Characterization of MVs from NPC cells.

MVs are characterized as being within the 100 to few micrometers size range (26). In order to confirm size range of these MVs harvested from NPC cells with or without LMP1, Transmission Electron microscopy (TEM) imaging was performed. Both the HK1 and HK1 GFP LMP1 inducible MV subpopulations were visualized to be around 200nm and exhibited similar phenotypes under the microscope, as seen in (Fig. 3A and B). Additionally, nanoparticle tracking was performed to further validate the EM results and to identify differences in MVs harvested from NPC cells expressing LMP1 compared to wild type NPC cells. The tracking data in (Fig. 3C) revealed that there was a significant increase in particles/ml for the MVs harvested from the high expressing LMP1 NPC cell line compared to the wild type cell line, however, there was no significant difference in particles/cell between the two cell lines (Fig. 3D). This is different than what was previously observed for enhancement of small EV production due to LMP1 expression (27). The reasoning to why increased particles per ml is observed could be due to the fact that NPC cells expressing LMP1 grow at a faster rate than the wild type cells resulting in more MVs being released per ml of media. Both the mean and mode size of the MVs secreted from the high LMP1 expressing cell line was significantly increased compared to wild type MVs (Fig. 3E and F). This led us to question whether these larger secreted MVs carry more protein cargo. The tracking and protein analyses revealed that the MVs from the high expressing LMP1 cell line had a significant increase in total protein

content compared to the wild type MVs (Fig. 3F). The nanoparticle tracking data suggests that there are not more MVs secreted per cell in the high expressing LMP1 cells but there is more protein per MV. Therefore, cells expressing LMP1 secrete larger MVs with increased protein content that may alter the immune response within the infected microenvironment.

PD-L1 is enhanced on the surface of MVs due to LMP1.

PD-L1 has previously been reported to be expressed on the surface of small EVs similar to cell surface PD-L1 membrane topology, in which the extracellular domain of PD-L1 is surface exposed (28). PD-L1 extracellular exposure is required for it to exert its immunosuppressive effects, since PD-L1 needs to be exposed on the surface to bind to its receptor PD-1 which is found on cytotoxic T cells. Flow cytometry on MVs from HK1 wild type cells and HK1 LMP1 induced cells expressing LMP1 was done. The MVs from both cell lines were incubated with surface PD-L1 antibody or isotype control. Flow cytometry analyses revealed elevated surface PD-L1 expression in the MVs from HK1 GFP tagged LMP1 (green) compared to the MVs from the HK1 wild type cells (blue) (Fig. 4A). In order to further understand PD-L1 localization on these MVs, scanning transmission electron microscopy (STEM) was undertaken to observe the MVs after immunogold labelling of PD-L1 with antibodies that specifically bind to PD-L1 on the extracellular domain. Upon examination of both the prepared EM grids, gold labelling of PD-L1 was only observed on the HK1 LMP1 MVs (Fig. 4B and C). Quantification of gold particles per MV revealed a significant increase in gold particles in the HK1 LMP1 MVs compared to the wild type MVs (Fig. 4D). Research has shown PD-L1 localization to be on the surface of small EVs; however, more current studies have found PD-L1 to be present on both the surface and within small EVs (29). To further understand PD-L1 localization within the MV, a protease protection experiment was done using two different PD-L1 antibodies. For this

experiment, Syntenin and CD71 were used as the positive and negative controls, respectively. Syntenin is a cytosolic adaptor located within EVs that binds to the intracellular domain (ICD) of syndecans (30), and CD71 is a transferrin receptor found on the surface of EVs. In (Fig. 4E), a PD-L1 antibody that recognizes endogenous levels of PD-L1 showed a decrease in band size upon the addition of trypsin. In (Fig. 4F) a PD-L1 antibody that recognizes the extracellular domain of PD-L1 was used, and upon trypsin addition little PD-L1 is observed. This reveals that there is some PD-L1 surface exposure on these MVs secreted from high LMP1 expressing cells; however, some PD-L1 may also be present inside MVs or is resistant to Trypsin cleavage. Taken together, LMP1 seems to play a role in increasing PD-L1 exposure to the surface of MVs which may influence the immunosuppressive effects of MVs released from EBV infected cells.

LMP1 and PD-L1 localize within the same MV subpopulation.

LMP1 and PD-L1 have previously been demonstrated to be expressed on small EVs (28, 31). Here, we aimed to investigate whether LMP1 was present in PD-L1 positive MVs following LMP1 induction of NPC cells. First, Optiprep density gradient purification of MVs was performed. This technique uses iodixanol and ultra-centrifugal force to further purify EV subpopulations into fractions based on their buoyant density (24) . This can be used to determine the exact density and fractions within the MV pellet that contain PD-L1 and whether it co-migrates with LMP1 in the gradient. MVs were harvested from doxycycline-treated HK1 GFP-LMP1 tetracycline-inducible cells and separated by density. The vesicles were purified on an iodixanol density gradient to separate larger MV subpopulation according to the method of Kowal et al (24). Two major populations of vesicles were observed in fractions 3 (F3) and 5 (F5) of the gradients, corresponding to densities 1.115 g/mL (third fraction = F3) and 1.145

g/mL (fifth fraction = F5) of iodixanol. MV subpopulations, F3 and F5 have previously been determined to be enriched with specific proteins. F3 usually contains unique ribosome and proteasome proteins with F5 containing more mitochondrial and ER proteins (24). In these experiments, F3 and F5 MV subpopulation of EVs were enriched for protein markers LMP1, PD-L1, and Caveolin-1 (Fig. 5A). LMP1 is present in both small EVs and larger shed microvesicles (31, 32). Furthermore, we demonstrate the co-migration of LMP1 and PD-L1 in fractions 3, 4 and 5. Fractions 3 and 5 were enriched with LMP1, PD-L1 and Caveolin-1 more so than the other fractions indicating that both LMP1 and PD-L1 co-migrate within the same density fractions in MVs. If LMP1 is present in PD-L1 positive MVs, then MVs immunoprecipitated with PD-L1 specific antibodies should contain LMP1. To test this, MVs were harvested from cells expressing LMP1 and recovered by the addition of anti-PD-L1 antibody. Ten percent of the MV input sample was used to compare to the PD-L1 immuno-precipitated MVs. Immunoblot analysis further revealed LMP1 to be present in the PD-L1 pulldown (Fig. 5B). EGFR was also pulled down in these PD-L1 positive MVs which was interesting since it has been recently demonstrated that EGFR activity can control PD-L1 surface presentation in breast cancer cells (33). Together, this data suggests that LMP1 and PD-L1 are likely in the same MV population (mostly in fractions 3 and 5) and are localized to the same vesicle within MVs.

LMP1 and PD-L1 colocalize in NPC cells and are enriched in lipid rafts.

NPC cells have enhanced levels of PD-L1 fluorescence expression in cells that are EBV+ compared to EBV- (34). Based on the above, it was hypothesized that LMP1 might be responsible for this observation possibly even altering PD-L1 subcellular localization. Similarly, the results from (Fig. 6A-E) demonstrate enhanced PD-L1 expression and perinuclear

colocalization with LMP1 in two different NPC cell lines (HK1 and HNE-1). Maximum intensity orthogonal projections of Z-stack colocalization images demonstrate PD-L1 and LMP1 perinuclear localization in live and fixed cell images (Fig. 6A and C). HNE-1 cells were transfected with RFP-tagged LMP1 and GFP-tagged PD-L1 and were examined by live cell confocal microscopy. The cells exhibited a distinct punctate perinuclear signal for LMP1 and PD-L1 (Fig. 6A). To confirm these results with endogenous levels of PD-L1 expression, and to understand what LMP1 does to PD-L1 localization within the cell, fixed cell imaging was done for HK1 LMP1 cells that were induced and un-induced with doxycycline. As seen in (Fig. 6B), PD-L1 is mostly localized perinuclearly when LMP1 is present. It seems to aggregate to one side of the cell in accordance to where LMP1 is also being accumulated. However, in the un-induced images lacking LMP1, PD-L1 was found to be mostly dispersed throughout the cell rather than localized within a sub-region like when LMP1 is present (Fig. 6C). Pearson's correlation coefficient between LMP1 and PD-L1 in the HNE-1 transfected cells and the induced HK1 LMP1 cells, was around 0.7 and 0.8 respectively, indicating a strong correlation between these two variables (Fig. 6B and D). Additionally, CTCF values were calculated for HK1 LMP1 cells with and without doxycycline and showed very high significance in levels of PD-L1 fluorescence in the doxycycline induced HK1 LMP1 cells compared to the un-induced (Fig. 6E).

LMP1 accumulates in lipid raft microdomains within the cell to engage signaling pathways (35). Lipid rafts are distinct lipid domains enriched in cholesterol and glycosphingolipids that are involved in many roles which include but are not limited to signal transduction, membrane trafficking and the lateral compartmentalization of molecules at the cell surface (35, 36). Both viruses and MVs emerge from the plasma membrane at lipid raft organizing centers indicating

a similar mechanism of biogenesis (14). The formation of MVs involves the transport of specific cargo to the plasma membrane, lipid membrane redistribution and finally a form of vesicle pinching off upon reaching the membrane which leads to the release of the vesicle (12). To test whether PD-L1 also accumulates in membrane microdomains, lipid rafts were isolated from wild type HK1 or HK1 LMP1 cells following induction of LMP1 based on their detergent-resistant biochemical properties and analyzed by immunoblot. In both cell lines raft isolates were enriched in lipid raft scaffolding protein Caveolin-1 (37). The adaptor protein Syntenin-1 was probed for since it is required for efficient LMP1 EV incorporation (25). As seen in (Fig. 6F), LMP1 and PD-L1 are enriched in lipid rafts; however, very little PD-L1 is present in wild type HK1 cells or rafts lacking LMP1. Based on this data, we conclude that PD-L1 is not only enhanced by LMP1 at the cellular level but also shifts PD-L1 localization from dispersed throughout the cell to colocalizing with LMP1 at perinuclear regions within the cell; additionally, PD-L1 and LMP1 may share a similar lipid raft associated mechanism of MV incorporation.

Discussion:

In this study, we examined the impact of EBV oncoprotein LMP1 on MV associated PD-L1 levels using a number of techniques. LMP1 has previously been found to contribute to immune evasion strategies and protect virus infected cells through the activation and upregulation of multiple immune-associated proteins (38). Moreover, LMP1 modified EVs are found to contribute to tumor progression through shaping the tumor microenvironment by enhancing tumor cell growth, migration, invasion, and suppressing the anti-tumor host response (39). LMP1 from infected cancer cells accumulate in small EVs (40). Numerous observations indicate that full-length LMP1 protein is secreted from

the cell in larger EVs shed from the cell surface called microvesicles (MVs) (41). The release of LMP1 from the cell through EV pathways has been suggested as a method of escape from degradation and cell-to-cell transmission of LMP1 and associated proteins (2, 3).

Recently, LMP1 has been found to regulate PD-L1 expression at the cellular level through STAT3, AP-1, and NF- κ B pathways (34). Cytokines such as tumor necrosis factor- α (TNF- α), interferon- γ (IFN- γ), and interleukin 4 (IL-4) upregulate PD-L1 expression through the STAT and NF- κ B pathways (43–45). IFN- γ also has been shown to have a synergetic effect with LMP1 in up-regulating PD-L1 in NPC (34). PD-L1 upregulation has been implicated in numerous roles with regards to immune suppression (28, 43, 44). Constitutive expression of PD-L1 on tumor cells is an innate immunity mechanism activated by several pro-survival pathways: MAPK (45), ATM/ATR/Chk1 (46), JAK/STAT (43), and PI3/AKT(44); or by genetic aberrations such as CDK5 disruption (47), loss of PTEN (48), or truncation of the 3'–UTR that stabilizes an increase in PD-L1 transcripts (49). However, constitutive expression of PD-L1 is far less common than IFN induced PD-L1 expression. PD-L1 is expressed in various cancers: gastric cancer (50), melanoma (51), nasopharyngeal carcinoma (52), post-transplant lymphoproliferative disorder (53), non-small cell lung cancer (54), pancreatic cancer (55), lymphomas (56), bladder cancer (57), kidney cancer (58), breast cancer (59), and Hodgkin lymphoma (60) . Other than EBV, multiple human herpes virus infections have also been found to result in increased PD-L1 expression such as herpes simplex virus (61), Varicella zoster virus (62), Cytomegalovirus (63), Human herpesvirus 6 (64), and Kaposi's sarcoma-associated herpesvirus (65). Interestingly, in addition to

human herpes viruses, infection with human immunodeficiency virus (HIV), influenza virus, Ebola virus, and adenovirus also leads to elevated PD-L1 expression (66), (67). Altogether, the wide array of diseases viral and non-viral, that are associated with increased PD-L1 expression emphasizes the need for elucidating the mechanism of pathway regulation, activation, and localization of PD-L1.

In immune competent hosts, EBV efficiently infects B lymphocytes, this initiates a strong cytotoxic T cell response against lytic and latent antigens, leading to the expansion of EBV-transformed B cells. To establish and maintain latency, EBV has adopted many immune evasion mechanisms. To further understand the function of PD-L1 in EBV related cancers in response to EBV viral oncogene LMP1, we characterized the subpopulations of extracellular vesicles expressing PD-L1 following LMP1 expression. In our experiment we determined PD-L1 enrichment in MVs in response to LMP1 levels in both a high LMP1 expressing cell line construct (HK1 GFP-tagged inducible LMP1) and by a LMP1 expressing cell line (HNE-1 pBabe LMP1) which constitutively expresses lower levels of LMP1, similar to levels found in EBV infected cells. It was observed that LMP1 and PD-L1 accumulated in a subpopulation of EVs called MVs. Additionally, we determined that the upregulation of PD-L1 in the MV subpopulation was in response to EBV LMP1. MVs from NPC cells were confirmed through size, density and the detection of MV markers. Flow cytometry analyses indicated an approximately 10-fold increase in PD-L1 associated MVs from the NPC cell line expressing LMP1 compared to the wild type. LMP1 upregulated the cellular expression of PD-L1 at the transcriptional level; however interestingly, PD-L1 mRNAs were detected in MVs. PD-L1 is post-transcriptionally regulated in an indirect way through TNF α -activated NF- κ B (68).

LMP1 is a CD40 receptor mimic that constitutively activates NF- κ B (69, 70). This depicts a mechanism in which PD-L1 is possibly being upregulated at the transcriptional level in MVs through the activation of NF- κ B by LMP1.

Moreover, we demonstrate that LMP1 expression in NPC cells results in total elevated levels of EV secretion and enhanced packaging of proteins within the MV. One possible explanation for the increase in protein per MV may be that EVs released from virally infected cells can package more proteins involved in suppressing the immune response toward the virus and consequently enhancing viral spread. LMP1 also appears to play a role in enhancing PD-L1 surface exposure in MVs. Enhanced PD-L1 surface levels could depict the mechanism in which LMP1 contributes to immune suppression by enhancing PD-L1-PD-1 interaction and T cell inactivation. LMP1 and PD-L1 also co-migrate within the same density gradient, and immuno-isolation of this MV subpopulation confirmed the presence of LMP1 in PD-L1 containing vesicles from an LMP1 expressing NPC cell line. EGFR was also immuno-isolated within the same MV with LMP1 and PD-L1. Recently, EGFR has been found to play a vital role in upregulating PD-L1 once activated, mediating immune escape in non-small cell lung cancer (71). LMP1 signaling occurs through localization in lipid rafts and by recruiting key signaling components to internal lipid raft containing membranes (35, 72). Our observations indicate that both LMP1 and PD-L1 colocalize perinuclearly within the cell and are enriched in lipid rafts which suggests a similar signaling platform between these two proteins, bringing together numerous signaling components that drive immune evasion mechanisms, and facilitates their interaction. These findings lead us to conclude that LMP1 might have different roles in different subpopulations of EVs, and

that LMP1 modified MVs may act as an instrumental component contributing to immune suppression and evasion of EBV viral infected cells, by the enhanced packaging of proteins into these MVs, with one of them being PD-L1.

Altogether, the above data suggests that EBV+ related diseases are largely dependent on PD-L1 for disease progression and possibly immune protection, and identifies a more specific target for treating these diseases. Therefore, any immunotherapy treatments targeted at disrupting this pathway could lead to better outcomes for patients suffering from EBV related diseases. One form of treatment for cancers that induce PD-L1 expression is immunotherapy which serves to boost the immune antitumor response and has fewer side effects than alternative cancer therapies, such as chemotherapy, surgery, and radiation. FDA approved antibodies pembrolizumab (73) and nivolumab (74) that target PD-1 and atezolizumab (75) that targets PD-L1, improve survival against Hodgkin's lymphoma (73, 75). Anti-PD-1 antibody is effective in several other cancers, such as glioblastoma (76), and metastatic melanoma (28). In addition to cancer, anti-PD-1/PD-L1 treatment has also been considered as a possible treatment for patients with dementia and Alzheimer's (77). Moreover, monoclonal antibodies targeting PD-1 or PD-L1 are now in phase I-II trials as a therapeutic treatment for patients with metastatic/recurrent NPC (78). Using anti-PD-1 or anti-PD-L1 ligands alone is usually insufficient. Unfortunately, using several immune blockade therapies increases the patient's likelihood of experiencing unwanted side effects (79).

Now that EBV's role in the regulation of PD-L1 has been established, exploring other viral functions that might be inducing MV associated PD-L1, such as EBV microRNAs,

EBNA-1/2, and LMP1/2A should be investigated. Targeting both LMP1 and PD-L1 expressing MVs and small EVs in EBV+ tumors might lead to a synergistic inhibitory effect on tumor growth and metastasis. Identifying post-treatment levels of MV levels of PD-L1 with anti- PD-L1 blockade therapy could help distinguish patients who respond to this specific type of therapy early on. Tumor genomic profiling is therefore necessary in order to prescribe the most effective treatment that will confer the best results with the least amount of toxicity and side effects to the patient. Additionally, determining the best way to overcome PD-L1 blockade resistance and detect/target MV associated PD-L1 are the necessary next steps to take in the PD-L1 therapeutic research domain. These results highlight the crucial role that MV associated PD-L1 might be playing in creating an immunosuppressive environment that cancers and possibly other diseases exploit. As more research on MV associated PD-L1 in EBV related cancers is conducted, its vital role in facilitating tumor progression can be elucidated.

The results from this research contribute to the EV field and PD-L1 immune-targeted therapies in several ways. Determining that MVs derived from EBV+ cell lines express PD-L1, identifies a new therapeutic target in immune blockade therapy. Consequently, determining whether PD-L1 localization is based on cell line, or on levels of LMP1 will help clarify the mechanisms that promote immune suppression since PD-L1 surface exposure is necessary for T cell inactivation. The next steps include determining the immunosuppressive functions of MV surface expressed PD-L1 in EBV related cancers and determining if they differ from PD-L1 function within small EVs. This immunosuppressive contribution could equate to exosomal levels of PD-L1 or may play a more vital role in immune suppression. In conclusion, we expect that our findings will

begin to clarify the mechanism of LMP1-mediated enhanced packaging of PD-L1 into MVs and the functions of LMP1-modified MVs. In terms of clinical applications, it could also serve as a potential therapeutic target or diagnostic biomarker for identifying whether or not the patient will respond well to immunotherapy treatment and predict tumor responses.

Materials and Methods:

Retrovirus production.

Retrovirus particles for transduction and stable cell generation were produced in HNE-1 cells following JetPrime transfection of expression plasmids (pBabe neo, pBabe-HA-LMP1 neo) and packaging plasmids pMD2.G (Addgene; number 12259; a gift from Didier Trono) and PSPAX2 (Addgene; number 12260; a gift from Didier Trono) according to the manufacturer's instructions (Polyplus). Medium was collected at 48, 72, and 96 h post-transfection, centrifuged for 10 min at 1,000 × *g*, filtered through a 0.45-μm filter, and frozen at −80°C until use. Stable HNE1 cell lines expressing pBabe-HA-LMP1 were created by retrovirus transduction as described above and were selected and maintained in 1 mg/ml of G418 sulfate.

Generation of GFP-LMP1-inducible cells

HK1 cells that stably express GFP-LMP1 under control of a tetracycline-inducible promoter were created by first being transduced with lentivirus particles containing pLenti CMV TetR BLAST (Addgene; 17492) as previously described in (18). Stable cells were selected with medium containing 10 μg/ml of blasticidin (InvivoGen; ant-bl-1) and then transduced with retrovirus particles containing pQCXP GFP-LMP1. Doubly stable

cells were selected with medium supplemented with blasticidin (10 µg/ml) and puromycin (2 µg/ml) for 2 weeks. LMP1 expression was induced for 24 h with the addition of doxycycline to a final concentration of 1 µg/ml or 0.5 µg/ml.

Cell culture.

HNE1 cells were cultured in 1:1 mixture of Dulbecco modified Eagle medium (DMEM; Lonza; 12-604Q) and Ham's F-12. HK1 (a gift from George Tsao, Hong Kong University). All cell culture Medium was supplemented with 10% fetal bovine serum (FBS; Seradigm; 1400-500), 2 mM L-glutamine (Corning; 25-005-CI), 100 IU of penicillin-streptomycin (Corning; 30-002-CI), and 100 µg/ml:0.25 µg/ml antibiotic/antimycotic (Corning; 30-002- CI). The cells were maintained at 37°C with 5% CO₂.

Transient Transfection

HK1 grown in 100 mm plates were transfected with 5 µg of RFP-LMP1 or GFP-PD-L1 plasmid using Lipofectamine 3000 transfection kit (Invitrogen, L3000015). Lipofectamine reagents were diluted in Opti-MEM medium (Gibco, 31,985–070) and added according to manufacturer's instructions. Twenty-four hours after transfection, cells were harvested and lysed in RIPA buffer, as previously described (25, 47). Cell-conditioned medium was harvested for extracellular vesicle enrichment.

Immunofluorescence assay

Cells were stained as previously described (47). The coverslips were coated with poly-L-lysine (Sigma; P1955) as according to manufacturer's instructions, then cells were seeded. The next day, cells had GFP-LMP1 induced using 0.5 µg/ml of doxycycline. The next day, cells were fixed in 100% ice-cold methanol or 4% paraformaldehyde for

10 minutes. Cells were then washed again with PBS 3 times before being permeabilized with 0.2% Triton-X in PBS. Cells were then placed in a blocking buffer (5% goat serum in PBS with 0.2% Tween [PBST]) for 30 minutes. Next, cells were stained with primary antibodies in blocking buffer PD-L1 D8T4X (1:200) for 2 hours. Cells were washed 3 times in PBST then placed in secondary antibody rabbit IgG (A48254; Thermo Fisher) diluted in the blocking buffer for 1 hour. Cells were washed 3 times with PBST before being incubated with Red DNA stain (52406; ENZO) diluted in PBS for 10 minutes. Cells were washed 2 times with PBS, and once with water before being mounted on a glass slide with mounting medium (4% propyl gallate, 90% glycerol in PBS) for confocal microscopy imaging. Confocal images were taken using a Zeiss LSM 880 microscope and processed using Zen 2.1 Black software.

Extracellular-vesicle enrichment.

Extracellular vesicles were harvested from conditioned cell culture media by differential centrifugation and polyethylene glycol (PEG) precipitation as previously described (80),(81). Briefly, apoptotic bodies/cell debris (2K), microvesicles (10K), and small EVs (100K) were harvested from cell-conditioned media by ultra-centrifugation at 2,000 RPM for 10 min, 10,000 RPM for 30 min, and by the ExtraPEG method respectively.

Protease Protection Experiment

After the washing step the MV pellet is resuspended in a 1:1 ratio of 0.25% trypsin and particle free PBS and left at 37°C for 30 minutes. This cleaves the surface membrane of the EV sample. Antibodies: (PD-L1 E1J2J; Cell Signaling) for extracellular domain of PD-L1, and (PD-L1 E1L3N; Cell Signaling) was used for endogenous levels of PD-L1. Sample is then resuspended in lysis buffer for immunoblot analysis.

Purification of membrane microdomains

Lipid raft (LR) microdomains were harvested as previously described (82).

Iodixanol density gradient.

EVs from HK1 GFP-LMP1-inducible cells and HNE1-pBabe-HA-LMP1 cells harvested by centrifugation for 10,000 $\times$ g for 30 min were further purified on a density gradient, according to the method of Kowal et al. (24). Briefly, EV pellets following the centrifugation step were re-suspended in 1.5 ml of 0.25 M sucrose buffer (10 mM Tris [pH 7.4]). A 60% stock (wt/vol) Optiprep (Sigma, D1556) solution was added 1:1 to EV suspensions and transferred to an MLS-50 rotor tube (Beckman; 344057). Iodixanol stock was then diluted in 0.25 M sucrose-Tris buffer to make 10% and 20% iodixanol solutions, and then 1.3 ml of 20% iodixanol and 1.2 ml of 10% iodixanol solutions were carefully layered on top of EV suspensions. Gradients were centrifuged for 90 min at maximum MLS-50 rotor speed (268,000 $\times$ g) and separated by collection of 490 μ l fractions from the top of the gradient. Densities were measured with a refractometer (Refracto 30PX). Individual fractions were washed with PBS and re-pelleted by ultracentrifugation in an SW41 Ti rotor at 100,000 $\times$ g for 2 h. Pellets were resuspended in particle-free PBS for NTA or strong urea-containing lysis buffer for immunoblot analysis.

Immunoblot analysis.

To prepare cell lysates, cells were washed and then scraped into cold PBS and collected by centrifugation at 1,000 $\times$ g for lysis in radio immune precipitation assay (RIPA) buffer (20 mM Tris-HCl, 50 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% deoxycholate) with 1X proteinase inhibitor. EV samples were harvested as described

above. To prepare all cell lysates, and EV lysates run under reducing conditions for SDS-PAGE, additional sample buffer (5×) also containing 0.2 M dithiothreitol (DTT) was added to samples. Lysates were boiled for 5 min. An equal protein concentration or equal volume of cell and EV lysate was run in an SDS 10% polyacrylamide gel and subsequently transferred onto a nitrocellulose membrane (GE Healthcare). Total protein was measured by Ponceau S stain. Blots were blocked with 5% (wt./vol.) nonfat dry milk powder in Tris-buffered saline with Tween 20 (TBS-T). Blots were probed with primary antibodies against the following: PD-L1 (E1L3N; Cell Signaling), Syntenin-1 (S-31; Santa Cruz), HSC70 (B-6; Santa Cruz), Caveolin-1 (D46G3; Cell Signaling), CD63 (TS63; Abcam), LMP1 (CS1-4; Dako), CD81 (B399; GeneTex), CD9 (CBL162; Millipore), CD71 (D7G9X; Cell Signaling), EGFR (SC-03; Santa Cruz). Blots were subsequently probed with the following horseradish peroxidase (HRP)-conjugated secondary antibodies: rabbit anti-mouse IgG (Genetex; 26728), or anti-mouse kappa light chain (H139-52.1; Abcam). Blots were imaged using an ImageQuant LAS4000 (General Electric) and processed with ImageQuant TL v8.1.0.0 software, Adobe Photoshop CS6, and Adobe illustrator.

Nanoparticle tracking.

Nanoparticle tracking analysis (NTA), a technology used to quantify nanoparticle concentrations and sizes consistent with EV populations, was used to determine increases in vesicle secretion and confirm size range of EV pellets following PD-L1 expression in cells. Following EV enrichment, vesicles were resuspended in particle-free PBS for quantitation using a Malvern NanoSight LM10 instrument as previously described in detail (83)(81). The camera level was set to 13, and the threshold was

maintained at 3 for all samples. The quantity of particles measured by NTA was normalized to the number of live cells counted at the time of harvest to generate a measure of the number of EVs secreted per cell. For nanoparticle tracking experiments, live cells were counted with an automated cell counter (Cellometer Vision, software version 2.1.4.2; Nexcelom Biosciences) at the time of harvest by staining with a 0.2% final concentration of trypan blue (Sigma; T8154) in phosphate-buffered saline (PBS) in a 1:1 ratio. Relative vesicle secretion was obtained by normalization of EV levels to control cells in each experiment.

Transmission electron microscopy.

Following enrichment of EVs by the ExtraPEG method, pellets were resuspended in 100 µl of particle-free PBS for electron microscopy imaging. Samples were prepared as described by Lässer et al. (84) and visualized on an FEI CM120 transmission electron microscope. For immunogold labelling, EV pellet was resuspended in anti-PD-L1 antibody (D8T4X; Cell Signaling) (1:60) in blocking buffer (1% BSA in PBS) for 2 hours. The EV suspensions were applied to formvar/carbon-coated nickel grids 200 mesh for 3 min. Then grids were washed with 5 separate drops (50 µl, 10 min per drop) of PBS with 0.1% BSA. Transferred a drop of the secondary antibody conjugated to 10 nm gold particle (Goat F(ab')₂ Anti-Rabbit IgG H&L (10nm Gold; ab39601) (1:100 in PBS with 0.1%BSA) to grids for 1 hour. Repeat washing steps. Next wash with 2 separate drops of fresh MilliQ. Finally, negative stain with uranyl acetate for 1 min.

Live cell imaging.

HNE-1 cells were seeded into 35-mm glass well plates (Greiner Bio-One; number 627860), co-transfected 24 h later with 1 µg of GFP tagged PD-L1 and RFP tagged

LMP1, and imaged 24 h post transfection using a Zeiss LSM 880 microscope with a live-cell imaging chamber. Hoechst 33342 nuclear staining (5 µg/ml; Thermo Scientific; number 62249) was added 15 min prior to imaging. Confocal images were taken and processed using Zen 2.1 Black software.

Immunoprecipitation

The MV sample obtained after centrifugation was resuspended in 1%BSA in PBS. 100 µl of magnetic G beads were washed 3 times with (0.1%BSA in PBS). Rabbit (DA1E) mAb IgG XP® Isotype Control or PD-L1 (Extracellular Domain Specific) (D8T4X) antibodies were diluted in PBS with 0.1% BSA and then mixed with 1.0 µg magnetic beads. The antibodies and magnetic beads were incubated with rotation for 20 min at room temperature. This was followed by three washes with 0.1% BSA in PBS. The Microvesicle sample was then added to the beads and left in the cold room for 3 hours with rotation. This was followed by another three washes with 0.1% BSA in PBS. Resuspended in 2x reducing buffer and then heat for 7 min at 90 °C before running on gel for immunoblot analysis.

Flow cytometry

Microvesicles from HK1 or HK1-LMP1 cell were first blocked with flow buffer (1% BSA in PBS) stained with either isotype control Ig or anti-PDL1 at 2g/mL for one hour at 4 °C. After wash with flow buffer, samples were stained with PE conjugated anti-rabbit antibody at 4 °C for 30 mins. Wash to remove unbound antibodies, samples were run on FACSC onto flow cytometer (BD) in Translational lab College of Medicine FSU. The data were analyzed by FACSDiva software (BD).

RNA Isolation and Reverse Transcription

Total RNA of cell or EV samples were isolated by Trizol reagent (ThermoFisher, 15596018) and quantified by nanodrop. Less than 1 µg of total RNA was used for reverse transcription by qScript cDNA SuperMix (Quantabio, 95048). CDNAs were store in -20°C until further use.

Quantitative Real-Time PCR and Data analysis

Standard 3-step cycles protocol (40 cycles of 95 °C for 5 s, 60 °C for 10 s, 72 °C for 20 s) was used in all qPCR reactions. PerfeCTa SYBR Green FastMix (Quantabio, 95072-012), assay primers (250 nM) and cDNA (1.0 µL) of cell or EV were prepared in 20 µL reaction and run on CFX96 qPCR machine (Bio-Rad). Gene expression level were first normalized to housekeeping gene GAPDH and then calculated with $\Delta\Delta C_t$ method.

qPCR primer sequence:

Gene ID (Aliases)	Sequence	Reference Primer Bank ID
GAPDH	GGAGCGAGATCCCTCCAAAAT	378404907c1
	GGCTGTTGTCATACTTCTCATGG	
CD274 (PD-L1)	CCTACTGGCATTGCTGAACGCAT	PNAS December 30, 2008 105 (52) 20852- 20857
	ACCATAGCTGATCATGCAGCGGTA	
CD9	TTCCTCTTGGTGATATTCGCCA	319738657c2
	AGTTCAACGCATAGTGGATGG	
CD63	CAGTGGTCATCATCGCAGTG	91199544c1
	ATCGAAGCAGTGTGGTTGTTT	
CD81	TTCCACGAGACGCTTGACTG	62240999c2
	CCCGAGGGACACAAATTGTTC	

SDCBP (Syntenin-1)	TGGCTCCTGTAAGTGGTAATGA	55749522c2
	CTCAGACCAACCAATGAGGCT	
HRS	AACGACAAGAACCCACACGTC	315138978c2
	GGCCTGGATCAGGTACAGGA	

585

586 **Data and statistics analysis**

587 Statistical analysis was performed using the GraphPad Prism 8 (GraphPad Software, San
588 Diego, CA) or Microsoft Excel with a significant threshold of $p \leq 0.05$. Pearson correlation
589 coefficient (PCC) was determined using an ImageJ colocalization plugin, with a minimum of 10
590 cells analyzed. The ImageJ software (NIH) was used to calculate the CTCF by applying this
591 formula: CTCF = integrated density (indicated by the software)-(Area of selected cell x Mean
592 fluorescence of background readings), as previously described (85). Statistical significance of
593 results was evaluated by unpaired t test with Welch's correction. Figures were constructed using
594 Adobe illustrator.

595 **Acknowledgments**

596 We would like to thank Dingani Nkosi and Sara York with their help on experiments and
597 useful discussions. Special thanks to Yah Xin at the National High Magnetic Field
598 Laboratory for help obtaining electron microscopy images and the FSU College of
599 Medicine Confocal Microscopy Laboratory. This research was supported by a grant
600 from the National Cancer Institute of the National Institutes of Health (RO1CA204621)
601 awarded to D.G.M.

Author Contributions: Conceptualization, M.A. and D.G.M.; data curation, M.A. and L.S.; funding acquisition, D.G.M.; investigation, M.A. and L.S. methodology, M.A., L.S. and D.G.M; project administration, D.G.M.; software, M.A. and L.S.; supervision, D.G.M.; writing—original draft, M.A.; writing—review and editing, D.G.M. and L.S. All authors have read and agreed to the published version of the manuscript.

Conflict of Interest

The authors report no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References:

1. Young LS, Rickinson AB. 2004. Epstein–Barr virus: 40 years on. 10. Nat Rev Cancer 4:757–768.
2. Moon P-G, Lee J-E, You S, Kim T-K, Cho J-H, Kim I-S, Kwon T-H, Kim C-D, Park S-H, Hwang D, Kim Y-L, Baek M-C. 2011. Proteomic analysis of urinary exosomes from patients of early IgA nephropathy and thin basement membrane nephropathy. PROTEOMICS 11:2459–2475.
3. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. 2007. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 8:239–245.
4. Nakae S, Suto H, Iikura M, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. 2006. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol Baltim Md 1950 176:2238–2248.

621 5. Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Haining WN, Freeman GJ, Sharpe AH.
622 2017. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits
623 CD8 T cell cytotoxicity. *J Exp Med* 214:895–904.

624 6. Inaguma S, Wang Z, Lasota J, Sarlomo-Rikala M, McCue PA, Ikeda H, Miettinen M. 2016.
625 Comprehensive immunohistochemical study of programmed cell death ligand 1 (PD-L1). Analysis in
626 5536 cases revealed consistent expression in trophoblastic tumors. *Am J Surg Pathol* 40:1133–
627 1142.

628 7. Francisco LM, Sage PT, Sharpe AH. 2010. The PD-1 Pathway in Tolerance and Autoimmunity.
629 *Immunol Rev* 236:219–242.

630 8. Bi X-W, Wang H, Zhang W-W, Xia Z, Zhang Y, Wang L. 2016. PD-L1 Is up-Regulated By EBV-Driven
631 LMP1 through NF- κ b Pathway and Correlates with Poor Prognosis in Natural Killer/T-Cell
632 Lymphoma. *Blood* 128:4134–4134.

633 9. Nakayama A, Abe H, Kunita A, Saito R, Kanda T, Yamashita H, Seto Y, Ishikawa S, Fukayama M.
634 2019. Viral loads correlate with upregulation of PD-L1 and worse patient prognosis in Epstein–Barr
635 Virus-associated gastric carcinoma. *PLoS ONE* 14.

636 10. Ozturk V, Yikilmaz AS, Kilicarslan A, Bakanay SM, Akinci S, Dilek İ. 2020. The Triple Positivity for
637 EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma. *Clin Lymphoma*
638 *Myeloma Leuk* <https://doi.org/10.1016/j.clml.2019.11.021>.

639 11. Meckes DG, Raab-Traub N. 2011. Microvesicles and Viral Infection. *J Virol* 85:12844–12854.

640 12. D’Souza-Schorey C, Clancy JW. 2012. Tumor-derived microvesicles: shedding light on novel
641 microenvironment modulators and prospective cancer biomarkers. *Genes Dev* 26:1287–1299.

- 642 13. Lee H, Li C, Zhang Y, Zhang D, Otterbein LE, Jin Y. 2019. Caveolin-1 selectively regulates microRNA
643 sorting into microvesicles after noxious stimuli. *J Exp Med* 216:2202–2220.
- 644 14. Weber EA, Singh MV, Singh VB, Jackson JW, Ture SK, Suwunnakorn S, Morrell CN, Maggirwar SB.
645 2020. Novel Mechanism of Microvesicle Regulation by the Antiviral Protein Tetherin During HIV
646 Infection. *J Am Heart Assoc* 9.
- 647 15. Poste G, Nicolson GL. 1980. Arrest and metastasis of blood-borne tumor cells are modified by
648 fusion of plasma membrane vesicles from highly metastatic cells. *Proc Natl Acad Sci U S A* 77:399–
649 403.
- 650 16. Valenti R, Huber V, Filipazzi P, Pilla L, Sovena G, Villa A, Corbelli A, Fais S, Parmiani G, Rivoltini L.
651 2006. Human Tumor-Released Microvesicles Promote the Differentiation of Myeloid Cells with
652 Transforming Growth Factor- β -Mediated Suppressive Activity on T Lymphocytes. *Cancer Res*
653 66:9290–9298.
- 654 17. Tsai C-Y, Sakakibara S, Yasui T, Minamitani T, Okuzaki D, Kikutani H. 2018. Bystander inhibition of
655 humoral immune responses by Epstein-Barr virus LMP1. *Int Immunol* 30:579–590.
- 656 18. Hurwitz SN, Nkosi D, Conlon MM, York SB, Liu X, Tremblay DC, Meckes DG. 2017. CD63 Regulates
657 Epstein-Barr Virus LMP1 Exosomal Packaging, Enhancement of Vesicle Production, and
658 Noncanonical NF- κ B Signaling. *J Virol* 91.
- 659 19. Meckes DG, Shair KHY, Marquitz AR, Kung C-P, Edwards RH, Raab-Traub N. 2010. Human tumor
660 virus utilizes exosomes for intercellular communication. *Proc Natl Acad Sci* 107:20370–20375.

- 661 20. Brooks L, Yao QY, Rickinson AB, Young LS. 1992. Epstein-Barr virus latent gene transcription in
662 nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. *J Virol*
663 66:2689–2697.
- 664 21. Horikawa T, Sheen TS, Takeshita H, Sato H, Furukawa M, Yoshizaki T. 2001. Induction of c-Met
665 proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical
666 lymph node metastasis of nasopharyngeal carcinoma. *Am J Pathol* 159:27–33.
- 667 22. Chen J, Hu C-F, Hou J-H, Shao Q, Yan L-X, Zhu X-F, Zeng Y-X, Shao J-Y. 2010. Epstein-Barr virus
668 encoded latent membrane protein 1 regulates mTOR signaling pathway genes which predict poor
669 prognosis of nasopharyngeal carcinoma. *J Transl Med* 8:30.
- 670 23. Wasil LR, Wei L, Chang C, Lan L, Shair KHY. 2015. Regulation of DNA Damage Signaling and Cell
671 Death Responses by Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) and LMP2A in
672 Nasopharyngeal Carcinoma Cells. *J Virol* 89:7612–7624.
- 673 24. Kowal J, Arras G, Colombo M, Jouve M, Morath JP, Primdal-Bengtson B, Dingli F, Loew D, Tkach M,
674 Théry C. 2016. Proteomic comparison defines novel markers to characterize heterogeneous
675 populations of extracellular vesicle subtypes. *Proc Natl Acad Sci* 113:E968–E977.
- 676 25. Nkosi D, Sun L, Duke LC, Patel N, Surapaneni SK, Singh M, Meckes DG. Epstein-Barr Virus LMP1
677 Promotes Syntenin-1- and Hrs-Induced Extracellular Vesicle Formation for Its Own Secretion To
678 Increase Cell Proliferation and Migration. *mBio* 11:e00589-20.
- 679 26. Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis | Elsevier
680 Enhanced Reader.

27. Ceccarelli S, Visco V, Raffa S, Wakisaka N, Pagano JS, Torrisi MR. 2007. Epstein-Barr virus latent membrane protein 1 promotes concentration in multivesicular bodies of fibroblast growth factor 2 and its release through exosomes. *Int J Cancer* 121:1494–1506.
28. Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, Xia H, Man Q, Zhong W, Antelo LF, Wu B, Xiong X, Liu X, Guan L, Li T, Liu S, Yang R, Lu Y, Dong L, McGettigan S, Somasundaram R, Radhakrishnan R, Mills G, Lu Y, Kim J, Chen YH, Dong H, Zhao Y, Karakousis GC, Mitchell TC, Schuchter LM, Herlyn M, Wherry EJ, Xu X, Guo W. 2018. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. *Nature* 560:382–386.
29. Poggio M, Hu T, Pai C-C, Chu B, Belair CD, Chang A, Montabana E, Lang UE, Fu Q, Fong L, Billelloch R. 2019. Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. *Cell* 177:414-427.e13.
30. Grootjans JJ, Zimmermann P, Reekmans G, Smets A, Degeest G, Dürr J, David G. 1997. Syntenin, a PDZ protein that binds syndecan cytoplasmic domains. *Proc Natl Acad Sci* 94:13683–13688.
31. Keryer-Bibens C, Pioche-Durieu C, Villemant C, Souquère S, Nishi N, Hirashima M, Middeldorp J, Busson P. 2006. Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral Latent Membrane Protein 1 and the immunomodulatory protein galectin 9. *BMC Cancer* 6:283.
32. Vazirabadi G, Geiger TR, Coffin lii WF, Martin JM. 2003. Epstein-Barr virus latent membrane protein-1 (LMP-1) and lytic LMP-1 localization in plasma membrane-derived extracellular vesicles and intracellular virions. *J Gen Virol* 84:1997–2008.

33. Monypenny J, Milewicz H, Flores-Borja F, Weitsman G, Cheung A, Chowdhury R, Burgoyne T, Arulappu A, Lawler K, Barber PR, Vicencio JM, Keppler M, Wulaningsih W, Davidson SM, Fraternali F, Woodman N, Turmaine M, Gillett C, Franz D, Quezada SA, Futter CE, Von Kriegsheim A, Kolch W, Vojnovic B, Carlton JG, Ng T. 2018. ALIX Regulates Tumor-Mediated Immunosuppression by Controlling EGFR Activity and PD-L1 Presentation. *Cell Rep* 24:630–641.
34. Fang W, Zhang J, Hong S, Zhan J, Chen N, Qin T, Tang Y, Zhang Y, Kang S, Zhou T, Wu X, Liang W, Hu Z, Ma Y, Zhao Y, Tian Y, Yang Y, Xue C, Yan Y, Hou X, Huang P, Huang Y, Zhao H, Zhang L. 2014. EBV-driven LMP1 and IFN- γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. *Oncotarget* 5:12189–12202.
35. Meckes DG, Menaker NF, Raab-Traub N. 2013. Epstein-Barr Virus LMP1 Modulates Lipid Raft Microdomains and the Vimentin Cytoskeleton for Signal Transduction and Transformation. *J Virol* 87:1301–1311.
36. Brown DA, London E. 1998. Functions of lipid rafts in biological membranes. *Annu Rev Cell Dev Biol* 14:111–136.
37. Salzer U, Prohaska R. 2001. Stomatin, flotillin-1, and flotillin-2 are major integral proteins of erythrocyte lipid rafts. *Blood* 97:1141–1143.
38. Middeldorp JM, Pegtel DM. 2008. Multiple roles of LMP1 in Epstein-Barr virus induced immune escape. *Semin Cancer Biol* 18:388–396.
39. Jabalee J, Towle R, Garnis C. 2018. The Role of Extracellular Vesicles in Cancer: Cargo, Function, and Therapeutic Implications. *Cells* 7:93.

40. Verweij FJ, van Eijndhoven MAJ, Hopmans ES, Vendrig T, Wurdinger T, Cahir-McFarland E, Kieff E, Geerts D, van der Kant R, Neefjes J, Middeldorp JM, Pegtel DM. 2011. LMP1 association with CD63 in endosomes and secretion via exosomes limits constitutive NF- κ B activation. *EMBO J* 30:2115–2129.
41. Flanagan J, Middeldorp J, Sculley T 2003. Localization of the Epstein–Barr virus protein LMP 1 to exosomes. *J Gen Virol* 84:1871–1879.
42. Dukers DF, Meij P, Vervoort MBHJ, Vos W, Scheper RJ, Meijer CJLM, Bloemena E, Middeldorp JM. 2000. Direct Immunosuppressive Effects of EBV-Encoded Latent Membrane Protein 1. *J Immunol* 165:663–670.
43. Moon JW, Kong S-K, Kim BS, Kim HJ, Lim H, Noh K, Kim Y, Choi J-W, Lee J-H, Kim Y-S. 2017. IFN γ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma. *Sci Rep* 7:17810.
44. Lastwika KJ, Wilson W, Li QK, Norris J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM, Yao S, Liu LN, Gills JJ, Dennis PA. 2016. Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. *Cancer Res* 76:227–238.
45. Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, Wilkerson MD, Fecci PE, Butaney M, Reibel JB, Soucheray M, Cohoon TJ, Janne PA, Meyerson M, Hayes DN, Shapiro GI, Shimamura T, Sholl LM, Rodig SJ, Freeman GJ, Hammerman PS, Dranoff G, Wong K-K. 2013. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. *Cancer Discov* 3:1355–1363.

46. Sato H, Niimi A, Yasuhara T, Permata TBM, Hagiwara Y, Isono M, Nuryadi E, Sekine R, Oike T, Kakoti S, Yoshimoto Y, Held KD, Suzuki Y, Kono K, Miyagawa K, Nakano T, Shibata A. 2017. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. *Nat Commun* 8:1751.
47. Dorand RD, Nthale J, Myers JT, Barkauskas DS, Avril S, Chirieleison SM, Pareek TK, Abbott DW, Stearns DS, Letterio JJ, Huang AY, Petrosiute A. 2016. Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. *Science* 353:399–403.
48. Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, Wang HY, Wysocka M, Cheng M, Ruggeri BA, Wasik MA. 2008. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). *Proc Natl Acad Sci U S A* 105:20852–20857.
49. Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, Maeda T, Nagata Y, Kitanaka A, Mizuno S, Tanaka H, Chiba K, Ito S, Watatani Y, Kakiuchi N, Suzuki H, Yoshizato T, Yoshida K, Sanada M, Itonaga H, Imaizumi Y, Totoki Y, Munakata W, Nakamura H, Hama N, Shide K, Kubuki Y, Hidaka T, Kameda T, Masuda K, Minato N, Kashiwase K, Izutsu K, Takaori-Kondo A, Miyazaki Y, Takahashi S, Shibata T, Kawamoto H, Akatsuka Y, Shimoda K, Takeuchi K, Seya T, Miyano S, Ogawa S. 2016. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. 7607. *Nature* 534:402–406.
50. Abe H, Kaneda A, Fukayama M. 2015. Epstein-Barr Virus-Associated Gastric Carcinoma: Use of Host Cell Machineries and Somatic Gene Mutations. *Pathobiol J Immunopathol Mol Cell Biol* 82:212–223.
51. Akiyama M, Matsuda Y, Arai T, Saeki H. 2020. PD-L1 expression in malignant melanomas of the skin and gastrointestinal tract. *Oncol Lett* 19:2481–2488.

52. Fang W, Zhang J, Hong S, Zhan J, Chen N, Qin T, Tang Y, Zhang Y, Kang S, Zhou T, Wu X, Liang W, Hu Z, Ma Y, Zhao Y, Tian Y, Yang Y, Xue C, Yan Y, Hou X, Huang P, Huang Y, Zhao H, Zhang L. 2014. EBV-driven LMP1 and IFN- γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. *Oncotarget* 5:12189.
53. Veloza L, Teixido C, Castrejon N, Climent F, Carrió A, Marginet M, Soldini D, González-Farré B, Ribera-Cortada I, Lopez-Guillermo A, González-Barca E, Sierra A, Herrera M, Gómez C, Garcia A, Balagué O, Campo E, Martinez A. 2019. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome. *Histopathology* 75:799–812.
54. Aggarwal C, Abreu DR, Felip E, Carcereny E, Gottfried M, Wehler T, Ahn M-J, Dolled-Filhart M, Zhang J, Shentu Y, Rangwala R, Piperdi B, Baas P. 2016. Prevalence of PD-L1 expression in patients with non-small cell lung cancer screened for enrollment in KEYNOTE-001, -010, and -024. *Ann Oncol* 27:vi363.
55. Zheng L. 2017. PD-L1 Expression in Pancreatic Cancer. *JNCI J Natl Cancer Inst* 109:djw304.
56. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MGM, Xu ML, Yu H, Fletcher CDM, Freeman GJ, Shipp MA, Rodig SJ. 2013. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. *Clin Cancer Res Off J Am Assoc Cancer Res* 19:3462–3473.
57. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata - Inman - 2007 - Cancer - Wiley Online Library.

58. Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, Albiges L, Bellmunt J, Song J, Carvo I, Lampron M, Stanton ML, Hodi FS, McDermott DF, Atkins MB, Freeman GJ, Hirsch MS, Signoretti S. 2014. PD-L1 expression in nonclear-cell renal cell carcinoma. *Ann Oncol* 25:2178–2184.
59. PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells.
60. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, Kutok JL, Shipp MA. 2010. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. *Blood* 116:3268–3277.
61. Jun H, Seo SK, Jeong H-Y, Seo H-M, Zhu G, Chen L, Choi I-H. 2005. B7-H1 (CD274) inhibits the development of herpetic stromal keratitis (HSK). *FEBS Lett* 579:6259–6264.
62. Jones D, Como CN, Jing L, Blackmon A, Neff CP, Krueger O, Bubak AN, Palmer BE, Koelle DM, Nagel MA. 2019. Varicella zoster virus productively infects human peripheral blood mononuclear cells to modulate expression of immunoinhibitory proteins and blocking PD-L1 enhances virus-specific CD8+ T cell effector function. *PLoS Pathog* 15:e1007650.
63. Benedict CA, Loewendorf A, Garcia Z, Blazar BR, Janssen EM. 2008. Dendritic cell programming by cytomegalovirus stunts naive T cell responses via the PD-L1/PD-1 pathway. *J Immunol Baltim Md* 1950 180:4836–4847.
64. Romeo MA, Gilardini Montani MS, Benedetti R, Giambelli L, D'Aprile R, Gaeta A, Faggioni A, Cirone M. 2021. The cross-talk between STAT1/STAT3 and ROS up-regulates PD-L1 and promotes the release of pro-inflammatory/immune suppressive cytokines in primary monocytes infected by HHV-6B. *Virus Res* 292:198231.

804 65. Ronaghy A, Wang H-Y, Thorson JA, Medeiros LJ, Xie Y, Zhang X, Sheikh-Fayyaz S. 2017. PD-L1 and
805 Notch1 expression in KSHV/HHV-8 and EBV associated germinotropic lymphoproliferative disorder:
806 case report and review of the literature. *Pathology (Phila)* 49:430–435.

807 66. Golrokh Mofrad M, Taghizadeh Maleki D, Faghihloo E. 2020. The roles of programmed death ligand
808 1 in virus-associated cancers. *Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis* 84:104368.

809 67. Schönrich G, Raftery MJ. 2019. The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance. *Front*
810 *Cell Infect Microbiol* 9:207.

811 68. Lim S-O, Li C-W, Xia W, Cha J-H, Chan L-C, Wu Y, Chang S-S, Lin W-C, Hsu J-M, Hsu Y-H, Kim T,
812 Chang W-C, Hsu JL, Yamaguchi H, Ding Q, Wang Y, Yang Y, Chen C-H, Sahin AA, Yu D, Hortobagyi
813 GN, Hung M-C. 2016. Deubiquitination and Stabilization of PD-L1 by CSN5. *Cancer Cell* 30:925–939.

814 69. Gires O, Zimmer-Strobl U, Gonnella R, Ueffing M, Marschall G, Zeidler R, Pich D, Hammerschmidt
815 W. 1997. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor
816 molecule. *EMBO J* 16:6131–6140.

817 70. Gewurz BE, Mar JC, Padi M, Zhao B, Shinnars NP, Takasaki K, Bedoya E, Zou JY, Cahir-Mcfarland E,
818 Quackenbush J, Kieff E. 2011. Canonical NF- κ B Activation Is Essential for Epstein-Barr Virus Latent
819 Membrane Protein 1 TES2/CTAR2 Gene Regulation ∇ . *J Virol* 85:6764–6773.

820 71. Chen N, Fang W, Zhan J, Hong S, Tang Y, Kang S, Zhang Y, He X, Zhou T, Qin T, Huang Y, Yi X, Zhang
821 L. 2015. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven
822 NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
823 *J Thorac Oncol Off Publ Int Assoc Study Lung Cancer* 10:910–923.

824 72. Rauch S, Fackler OT. 2007. Viruses, lipid rafts and signal transduction. *Signal Transduct* 7:53–63.

73. Dang TO, Ogunniyi A, Barbee MS, Drilon A. 2016. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. *Expert Rev Anticancer Ther* 16:13–20.
74. Guo L, Zhang H, Chen B. 2017. Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. *J Cancer* 8:410–416.
75. Krishnamurthy A, Jimeno A. 2017. Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers. *Drugs Today Barc Spain* 1998 53:217–237.
76. Ricklefs FL, Alayo Q, Krenzlin H, Mahmoud AB, Speranza MC, Nakashima H, Hayes JL, Lee K, Balaj L, Passaro C, Rooj AK, Krasemann S, Carter BS, Chen CC, Steed T, Treiber J, Rodig S, Yang K, Nakano I, Lee H, Weissleder R, Breakefield XO, Godlewski J, Westphal M, Lamszus K, Freeman GJ, Bronisz A, Lawler SE, Chiocca EA. 2018. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. *Sci Adv* 4.
77. Rosenzweig N, Dvir-Szternfeld R, Tsitsou-Kampeli A, Keren-Shaul H, Ben-Yehuda H, Weill-Raynal P, Cahalon L, Kertser A, Baruch K, Amit I, Weiner A, Schwartz M. 2019. PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model. *1. Nat Commun* 10:465.
78. Masterson L, Howard J, Gonzalez-Cruz J, Jackson C, Barnett C, Overton L, Liu H, Ladwa R, Simpson F, McGrath M, Wallwork B, Jones T, Ottensmeier C, Chua MLK, Perry C, Khanna R, Panizza B, Porceddu S, Lechner M. 2020. Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation? *Int J Cancer* 146:2305–2314.
79. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon R-A, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I,

- Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. 2013. Nivolumab plus Ipilimumab in Advanced Melanoma. *N Engl J Med* 369:122–133.
80. Hurwitz SN, Cheerathodi MR, Nkosi D, York SB, Meckes DG. 2018. Tetraspanin CD63 Bridges Autophagic and Endosomal Processes To Regulate Exosomal Secretion and Intracellular Signaling of Epstein-Barr Virus LMP1. *J Virol* 92:e01969-17.
81. ExtraPEG: A Polyethylene Glycol-Based Method for Enrichment of Extracellular Vesicles | Scientific Reports.
82. Nkosi D, Howell LA, Cheerathodi MR, Hurwitz SN, Tremblay DC, Liu X, Meckes DG. 2018. Transmembrane Domains Mediate Intra- and Extracellular Trafficking of Epstein-Barr Virus Latent Membrane Protein 1. *J Virol* 92:e00280-18.
83. Hurwitz SN, Conlon MM, Rider MA, Brownstein NC, Meckes DG. 2016. Nanoparticle analysis sheds budding insights into genetic drivers of extracellular vesicle biogenesis. *J Extracell Vesicles* 5:31295.
84. Lässer C, Eldh M, Lötvall J. 2012. Isolation and characterization of RNA-containing exosomes. *J Vis Exp JoVE* e3037.
85. Measuring cell fluorescence using ImageJ — The Open Lab Book v1.0.

Figures:

Fig 1. LMP1 expression in NPC cells leads to enhanced PD-L1 levels in MVs. Cell lysates, 2K, 10K, and 100K were loaded at equal protein concentration of 20µg. (A and B) Immunoblot analyses of HK1 GFP-tagged LMP1 and HNE-1 HA-tagged LMP1 demonstrate increased PD-L1 expression in the MV subpopulation compared to HK1

and HNE-1, respectively. (C and D) Quantification of 3 western blots from independent experiments demonstrate significantly higher levels of PD-L1 expression in MVs expressing LMP1 compared to control cell lines HK1 and HNE-1. (E and F) Quantification of 3 western blots in NPC cells expressing LMP1 revealed significantly higher levels of PD-L1 in the MVs compared to the other two EV subpopulations. **, $P < 0.01$; *, $P < 0.05$.

Fig 2. PD-L1 is upregulated at the transcriptional level in LMP1 expressing cells and is detected in MVs. RT-qPCR result of mRNA from normal HK1 cells or HK1 LMP1 induced cells (A) and MVs (B). The results were normalized to GAPDH. ***, $P < 0.001$; **, $P < 0.01$; *, $P < 0.05$.

Fig 3. Characterization of MVs from NPC cells. (A and B) MVs harvested by 10,000 RPM spin from HK1 and HK1 LMP1 induced cells were examined by electron microscopy. (C-G) Nanoparticle tracking analysis showed significant increase in particles/ml, microgram/particle, mean, and mode size but not in particles/cell from MVs harvested from HK1 LMP1 cells compared to HK1 control cells. ***, $P < 0.001$; **, $P < 0.01$; *, $P < 0.05$.

Fig 4. LMP1 enhances PD-L1 MV-associated surface levels. (A) Flow cytometry analysis on MVs harvested from HK1 and HK1 LMP1 induced cells stained for either isotype control or PD-L1 surface antibody. (B and C) PD-L1 immunogold labelling of HK1 and HK1 LMP1 MVs. (D)

Quantification of gold particles per MV from 10 HK1 and HK1 LMP1 induced MVs. (E and F) Immunoblot analyses of HK1 LMP1 MVs with and without trypsin. Different PD-L1 antibodies were used to probe for endogenous levels of PD-L1 (E) and extracellular domain specific PD-L1 (F). CD71 and Syntenin-1 are used as negative and positive controls, respectively. **, $P < 0.01$.

Fig 5. LMP1 and PD-L1 localize within the same MV subpopulation. (A) Immunoblot of iodixanol density gradient fractions of HK1 LMP1 MVs demonstrating the presence of two distinct populations enriched in LMP1, PD-L1, and Caveolin-1 corresponding to fractions (3 and 5), equal volumes loaded. (B) Immunoprecipitation of PD-L1, LMP1, and EGFR in HK1 LMP1 MVs. Equal volumes of control Rabbit IgG antibody, control rabbit IgG antibody and HK1 LMP1 MVs, and anti-PD-L1 antibody and HK1 LMP1 MVs were loaded. The first lane is 10% of the HK1 LMP1 MV sample loaded for comparison.

Fig 6. LMP1 and PD-L1 colocalize in NPC cells and are enriched in lipid rafts. All confocal images are Maximum Intensity Projections of Z-stacks, Scale bar: 10 μ m. (A) HNE-1 cells were transfected with GFP-tagged PD-L1, RFP-tagged LMP1, and Hoechst nuclear stain, for live-cell confocal microscopy. (C) HK1 GFP-tagged LMP1 cells induced or not induced with doxycycline were fixed, stained for PD-L1 (Alexa Fluor plus 405) and Nuclear-ID Red DNA stain and imaged by confocal microscopy. (B and D) Pearson's Correlation Coefficient for PD-L1 and LMP1 in the HNE-1 transfected cells and induced HK1 LMP1 cells was measured in 10 cells with a value of around 0.7 and 0.8, respectively. (E) Induced HK1 LMP1 cells

911 demonstrate significantly higher PD-L1 fluorescence compared to un-induced cells.
 912 Immunoblot analyses of whole cell lysates or lipid raft fraction of induced HK1 LMP1 cells or
 913 HK1 control cells demonstrate lipid raft enrichment of LMP1, PD-L1, and Caveolin-1. ****,
 914 $P < 0.0001$. CTCF=corrected total cell fluorescence.

915

Fig 1

Fig 1. LMP1 expression in NPC cells leads to enhanced PD-L1 levels in MVs. Cell lysates, 2K, 10K, and 100K were loaded at equal protein concentration of 20µg. (A and B) Immunoblot analyses of HK1 GFP-tagged LMP1 and HNE-1 HA-tagged LMP1 demonstrate increased PD-L1 expression in the MVsubpopulation compared to HK1 and HNE-1, respectively. (C and D) Quantification of 3 western blots from independent experiments demonstrate significantly higher levels of PD-L1 expression in MVs expressing LMP1 compared to control cell lines HK1 and HNE-1. (E and F) Quantification of 3 western blots revealed significantly higher levels of PD-L1 in the MVs compared to the other two EV subpopulations. **, P<0.01; *, P<0.05.

Fig 2

Fig 2. PD-L1 is upregulated at the transcriptional level in LMP1 expressing cells and detected in MVs. RT-qPCR result of mRNA from normal HK1 cells or HK1 LMP1 induced cells (A) and MVs (B). The results were normalized to GAPDH. ***, P<0.001; **, P<0.01; *, P<0.05.

Fig 3

Fig 3. Characterization of MVs from NPC cells. (A and B) MVs harvested by 10,000 RPM spin from HK1 and HK1 LMP1 induced cells were examined by electron microscopy. (C-G) Nanoparticle tracking analysis showed significant increase in particles/ml, microgram/particle, mean, and mode size but not in particles/cell from MVs harvested from HK1 LMP1 cells compared to HK1 control cells. ***, P<0.001 **; P<0.01; *, P<0.05.

Fig 4

Fig 4. MV-associated PD-L1 surface expression is enhanced by LMP1 expression. (A) Flow cytometry analysis on MVs harvested from HK1 and HK1 LMP1 induced cells stained for either isotype control or PD-L1 surface antibody. (B and C) PD-L1 immunogold labelling of HK1 and HK1 LMP1 MVs. (D) Quantification of gold particles per MV from 10 HK1 and HK1 LMP1 induced MVs. (E and F) Immunoblot analyses of HK1 LMP1 MVs with and without trypsin. Different PD-L1 antibodies were used to probe for endogenous levels of PD-L1 (E) and extracellular domain specific PD-L1 (F). CD71 and Syntenin-1 are used as negative and positive controls, respectively. **, P<0.01.

Fig 5

Fig 5. LMP1 and PD-L1 co-migrate and localize within the same MV subpopulation.

(A) Immunoblot of iodixanol density gradient fractions of HK1 LMP1 MVs demonstrating the presence of two distinct populations enriched in LMP1, PD-L1, and Caveolin-1 corresponding to fractions (3 and 5), equal volumes loaded. (B) Immunoprecipitation of PD-L1, LMP1, and EGFR in HK1 LMP1 MVs. Equal volumes of control Rabbit IgG antibody, control rabbit IgG antibody and HK1 LMP1 MVs, and anti-PD-L1 antibody and HK1 LMP1 MVs were loaded. The first lane is 10% of the HK1 LMP1 MV sample loaded for comparison.

Fig 6. LMP1 and PD-L1 colocalize in NPC cells and are enriched in lipid rafts. All confocal images are Maximum Intensity Projections of Z-stacks, Scale bar: 10µm. (A) HNE-1 cells were transfected with GFP-tagged PD-L1, RFP-tagged LMP1, and Hoechst nuclear stain, for live-cell confocal microscopy. (C) HK1 GFP-tagged LMP1 cells induced or not induced with doxycycline were fixed, stained for PD-L1 (Alexa Fluor plus 405) and Nuclear-ID Red DNA stain and imaged by confocal microscopy. (B and D) Pearson's Correlation Coefficient for PD-L1 and LMP1 in the HNE-1 transfected cells and induced HK1 LMP1 cells was measured in 10 cells with a value of around 0.7 and 0.8, respectively. (E) Induced HK1 LMP1 cells demonstrate significantly higher PD-L1 fluorescence compared to un-induced cells. Immunoblot analyses of whole cell lysates or lipid raft fraction of induced HK1 LMP1 cells or HK1 control cells demonstrate lipid raft enrichment of LMP1, PD-L1, and Caveolin-1. ****, P<0.0001 CTCF=corrected total cell fluorescence.